Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
全站搜尋
:::
▍發表論文
:::

2026年

  1. Yen FS, Wei JC, Lu WY, Yen YH, Wu YL, Lo YR, Hwu CM, Hsu CC. Income-related inequities in the progression from gestational to type 2 diabetes: Findings from Taiwan's maternal and child health database. Diabetes Obes Metab. 2026 Mar;28(3):1844-1853. (IF: 5.7)
  2. Yeh YK, Yen FS, Wei JC, Tsai YT, Lin HJ, Shih YH, Hsu CC, Hwu CM. The impact of pay-for-performance programs on hospitalization risks in subjects with type 1 diabetes mellitus: A nationwide cohort study. Prim Care Diabetes. 2026 Feb;20(1):68-73. (IF: 2.3)
  3. Association of GLP-1 Receptor Agonist Use With Chronic Kidney Disease Risk in Type 2 Diabetes: Multicenter Emulated Target Trials. Fu-Shun Yen, Chih-Cheng Hsu, Jing-Yang Huang, Chii-Min Hwu, James Cheng-Chung Wei. Mayo Clinic Proceedings. (accepted Jan 21, 2026) (IF: 6.7)
  4. Chin-Sung Kuo, Nai-Rong Kuo, Po-Hsun Huang, Chii-Min Hwu. The WATCH-DM integer-based risk score identifies risk of all-cause mortality in patients with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism. 2026-2 Accepted (IF 4.6)
  5. Chang CY, Hwu CM, Ou HY, Chen JF, Chen YC, Lee YJ, Huang CN, Hung YJ, Kuo FC. The status of depression associated with macrovascular and microvascular comorbidities in patients with long-duration type 2 diabetes: A cross-sectional study from the Taiwan diabetes registry. J Psychosom Res. 2026 Apr 7;207:112662. doi: 10.1016/j.jpsychores.2026.112662. Epub ahead of print. PMID: 41965133. (IF 3.3)
  6. Yen YH, Wei JC, Ko FS, Yen FS, Lin HJ, Li PY, Cho DY, Hwu CM, Hsu CC. Microvascular complications and risk of osteoporosis and fractures in type 2 diabetes: a nationwide Asian cohort study. J Endocrinol Invest. 2026 Apr 20. doi: 10.1007/s40618-026-02894-4. Epub ahead of print. PMID: 42002671. (IF 3.5)
  7. Chin-Sung Kuo, Nai-Rong Kuo, Fu-Shun Ko, Po-Hsun Huang, Chii-Min Hwu. Hemoglobin glycation index and renal progression in patients with type 2 diabetes: a 5-year cohort study. Endocrine. 2026 May 4;91(1):175. (IF 2.9)
  8. Yen FS, Hsu CC, Hung YM, Huang JY, Hwu CM*, Wei JC. Association of GLP-1 Receptor Agonist Use With Chronic Kidney Disease Risk in Type 2 Diabetes: Multicenter Emulated Target Trials. Mayo Clin Proc. 2026 Jun;101(6):909-919. doi: 10.1016/j.mayocp.2026.01.035. Epub 2026 Apr 21. PMID: 42012433. (IF: 6.5)
  9. Yen FS, Wei JC, Hung YM, Liu JS, Hwu CM*, Hsu CC. SGLT2 inhibitors and the risk of incident chronic kidney disease in type 2 diabetes: a nationwide emulated target trial in Taiwan. Diabetes Res Clin Pract. 2026 Jun;236:113267. doi: 10.1016/j.diabres.2026.113267. Epub 2026 Apr 17. PMID: 42002149. (IF: 4.6)
  10. Yen FS, Yen YH, Hung YM, Wei JC, Tsai FJ, Hung YT, Lin HJ, Hwu CM*, Hsu CC. Diabetic Microvascular Disease and Risk of Peripheral Artery Disease, Foot Ulcer, Leg Infection, and Amputation. Thromb Haemost. 2026 Jun;126(6):610-622. doi: 10.1055/a-2661-2537. Epub 2025 Aug 5. PMID: 40763784. (IF: 4.3)
  11. Ko FS, Su GY, Hwu CM**, Wu CL. Advances in body composition imaging for diagnosis and monitoring: From radiologic assessment to precision medicine. J Chin Med Assoc. 2026 Jun 2. doi: 10.1097/JCMA.0000000000001391. Epub ahead of print. PMID: 42226089. (IF: 2.3)
  12. Yen, Fu-Shun; Yen, Yu-Hsin; Hung, Yao-Min; Wei, James Cheng-Chung; Sung, Chen-Yu; Huang, Yu-Han; Tsai, Fuu-Jen; Hwu, Chii-Min*; Hsu, Chih-Cheng. Comparative risk of epilepsy with SGLT2 inhibitors vs. incretin-based therapies in type 2 diabetes. Epilepsia. 2026; 00: 1–14. https://doi.org/10.1002/epi.70369 (IF: 5.6)
  13. Chiang PW, Chen HS*. Prevalence and clinical correlates of pre-operative glucose homeostasis in patients with acromegaly. Growth Horm IGF Res. 2026 Feb 25;84:101686. (IF: 1.8)
  14. Huang C-J, Yang S-J, Cheng C-P, Lin C-H, Lee Y-C, Chen H-S. Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real-world experience. Diabet Med. 2026; 43:e70275. doi:10.1111/dme.70275 (IF: 3.4)
  15. Chen JW, Yu FT, Chen HA, Huang TF, Chen HS, Wu TE. Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort. Diabetes Metab. 2026 Mar;52(2):101740. doi: 10.1016/j.diabet.2026.101740. Epub 2026 Feb 11. PMID: 41687959. (IF: 4.7)
  16. Lee PS, Tseng CL, Chen JY, Chen HS, Huang CJ. Clinical Characteristics and Outcomes of Clinically Detected Versus Imaging-Detected Incidental Thyroid Cancer. Endocr Pract. 2026 May;32(5):769-778. doi: 10.1016/j.eprac.2026.02.005. Epub 2026 Feb 11. PMID: 41687737. (IF: 4.6)
  17. Lai YM, Chung IF, Huang SH, Sheu WH, Liang KH, Chen HS. A Deep Learning Prognostic Model for Diabetes Patients Using Bilateral Fundus Imaging. J Diabetes Sci Technol. 2026 Mar 29:19322968261434035. doi: 10.1177/19322968261434035. Epub ahead of print. PMID: 41905764; PMCID: PMC13033585. (IF 3.7)
  18. Wu TE, Chen HS. Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations. J Chin Med Assoc. 2026 Jun 1;89(6):407-414. doi: 10.1097/JCMA.0000000000001370. Epub 2026 Mar 17. PMID: 41857480; PMCID: PMC13286313. (IF 2.4)
  19. Tsung-Hui Wu, Chin-Sung Kuo, Harn-Shen Chen*. Effects of Insulin and Exenatide Therapy on Glycemic Control and β-Cell Function in Patients Newly Diagnosed with Type 2 Diabetes. Journal of the Chinese Medical Association. (accepted May 15, 2026) (IF: 2.3)
  20. Kuo CS, Kuo NR, Huang PH, Hwu CM. The WATCH-DM integer-based risk score identifies risk of all-cause mortality in patients with type 2 diabetes: a retrospective cohort study. Ther Adv Endocrinol Metab. 2026 Mar 23;17:20420188261431021. doi: 10.1177/20420188261431021. PMID: 41884313; PMCID: PMC13009881. (IF 4.6)
  21. Chin-Sung Kuo, Nai-Rong Kuo, Fu-Shun Ko, Po-Hsun Huang, Chii-Min Hwu. Hemoglobin glycation index and renal progression in patients with type 2 diabetes: a 5-year cohort study. Endocrine. 2026 May 4;91(1):175. (IF 2.9)
  22. Ya-Wen Lu, Chun-Chin Chang, Ruey-Hsing Cho, Chin-Sung Kuo*, Shih-Hung Tsai, Po-Hsun Huang. Insulin Resistance is Associated With Skin Microvascular Dysfunction and Reduced Circulating Endothelial Progenitor Cells in Hypertensive Patients. J Clin Hypertens (Greenwich). 2026 May;28(5):e70281. (IF 2.5)
  23. Yeh HY, Lu HF, Lin LY, *Chien LN. Risk of Diabetic Ketoacidosis with Sodium-Glucose Cotransporter-2 Inhibitors Compared with Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: A Nationwide Cohort Study. Ther Adv Chronic Dis 2026 Jan 14(accepted) (IF: 2.8)
  24. Liao TY, Lin YC, Huang CJ, Hwu CM, *Lin LY. Clinical efficacy and safety of fluconazole treatment in patients with Cushing's syndrome. Ther Adv Endocrinol Metab. 2025 Oct 21;16:20420188251372275. (IF:4.6)
  25. Hung TY, Lin TC, Liou YJ, Lin TH, Hsu YJ, *Lin LY, *Wang MT. Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with type 2 diabetes: A cohort study. J Intern Med. 2025 Sep;298(3):214-227. (IF:9.2)
  26. Lin LY, Lin YH, Chueh SJ, Yeh CF, Wu CC, Cheng HM, Hwang SJ, Liu FH, Yang J, *Wu VC. Universal Screening for Primary Aldosteronism in Hypertensive Patients: A 2025 Taipei Positional Paper. J Clin Hypertens (Greenwich). 2025 Sep;27(9):e70102. (IF:2.5)
  27. Huang CJ, Yang SJ, Cheng CP, Chen HS*. Efficacy and safety of switching to iGlarLixi from a premix insulin regimen in patients with Type 2 diabetes mellitus: a real world experience. Diabetic Medicine. (IF: 3.4) Accept on Feb 9, 2026.
  28. Po-Sheng Lee, Chi-Lung Tseng, Jui-Yu Chen, Harn-Shen Chen, Chun-Jui Huang*. Clinical Characteristics and Outcomes of Clinically Detected versus Imaging-Detected Incidental Thyroid Cancer. Endocrine Practice. 2026 Feb 11:S1530-891X(26)00781-0. (IF: 4.6)
  29. Huang CJ, Chen YW, Yang SJ, Li JZ, Hwu CM, Chen HS, Wang FF, Yang CC. Empirical comparison of iodine excretion estimated from spot urine samples with measured 24-hour urinary iodine excretion in healthy adults. J Chin Med Assoc. 2026 Apr 1;89(4):271-278. doi: 10.1097/JCMA.0000000000001363. Epub 2026 Mar 6. PMID: 41787684. (IF: 2.4)
  30. Lee CY, Chung RH, Zhuang YS, Rotter JI, Ida Chen YD, Sheu WH. Genetic evidence for causality of late chronotype on metabolic syndrome in East Asians and Europeans. Sleep Med. 2026 Feb 16;142:108845. (IF: 3.4)
  31. Huang SF, Wang FD, Huang CC, Chou KT, Huang YC, Wu PF, Lee CT, Yang YY. Monitoring treatment response using serial PTX3 levels in chronic and invasive pulmonary aspergillosis. Clin Chim Acta. 2026 Jan 1;578:120553. (IF: 2.9)

最後更新：

回到最上